“The FDA approval of ExAblate is an exciting next step in GE’s investment in InSightec,” Tom Gentile, president and CEO of GE Healthcare Systems and InSightec board member. “Pain is the most common and most severe symptom for patient’s suffering from bone cancer; we believe that ExAblate can help significantly improve the quality of life for patients. This is the first approved oncology application of ExAblate and we are excited that InSightec will continue researching in this area to expand the applications of this product.”
* Trademark of General Electric Company.
510(k) pending at U.S. FDA and not available for sale in the U.S.
GE Healthcare at RSNA 2012
Each year in Chicago, the conference of the Radiological Association of North America (RSNA) provides a forum for showcasing the latest innovations in medical imaging. If you are attending the conference, please visit GE Healthcare at booth number 5433 in McCormick Place south hall. Throughout the week of the event, GE Healthcare will distribute news and information using these digital platforms:
About GE Healthcare
GE Healthcare provides transformational medical technologies and services that are shaping a new age of patient care. Our broad expertise in medical imaging and information technologies, medical diagnostics, patient monitoring systems, drug discovery, biopharmaceutical manufacturing technologies, performance improvement and performance solutions services help our customers to deliver better care to more people around the world at a lower cost. In addition, we partner with healthcare leaders, striving to leverage the global policy change necessary to implement a successful shift to sustainable healthcare systems.